<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16362646</article-id><article-id pub-id-type="pmc">3452312</article-id><article-id pub-id-type="publisher-id">155</article-id><article-id pub-id-type="doi">10.1007/s10194-005-0155-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Topiramate in the treatment of refractory chronic daily headache. An open trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Mosek</surname><given-names>A.</given-names></name><address><phone>+972-3-697-4874</phone><fax>+972-3-697-4872</fax><email>mosek@tasmc.health.gov.il</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Dano</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">The Headache and Facial Pain Clinic, Department of Neurology, Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv 64239, Israel </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>4</month><year>2005</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2005</year></pub-date><volume>6</volume><issue>2</issue><fpage>77</fpage><lpage>80</lpage><history><date date-type="received"><day>18</day><month>10</month><year>2004</year></date><date date-type="accepted"><day>11</day><month>1</month><year>2005</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag
Italia 2005</copyright-statement></permissions><abstract id="Abs1"><p>Chronic daily headache (CDH) is a debilitating disorder that becomes a treatment challenge in patients refractory to the treatment. We hereby report our experience with topiramate treatment in patients with refractory CDH. The study design was a prospective, protocol&#x02013;based follow&#x02013;up and retrospective analysis of headache diaries. We treated with topiramate at slowly increased moderate increments 11 CDH patients who were refractory to multiple previous treatments. Topiramate treatment was effective in 7 (64%) patients. The treatment resulted in a 66% (median) decrease of the headache days per week and a significant decrease in headache severity, a reduction of the headache hours per day, and weekly analgesic consumption. These effects continued for an average follow&#x02013;up of 8&#x000b1;4 months. The average effective dose was 100 mg/day. Slowly increasing the drug at moderate increments resulted in high tolerability of topiramate. We found topiramate to be an effective long&#x02013;standing treatment option for patients with refractory CDH. Slow increments of the dosage contributed to high tolerability of the drug.</p></abstract><kwd-group xml:lang="en"><title>Key words</title><kwd>Topiramate</kwd><kwd>Chronic daily headache</kwd><kwd>Headache prevention</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag
Italia 2005</meta-value></custom-meta></custom-meta-group></article-meta></front></article>
